BCM
RIGL icon

Bayesian Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bayesian Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,048
Closed -$45.1K – 1038
2024
Q1 		$45.1K Buy
3,048
+1,910
+168% +$25.7K ﹤0.01% 737
2023
Q4 		$16.5K Sell
1,138
-370
-25% -$3.78K ﹤0.01% 697
2023
Q3 		$16.3K Sell
1,508
-1,280
-46% -$15.4K ﹤0.01% 656
2023
Q2 		$36K Sell
2,788
-5,782
-67% -$78.2K ﹤0.01% 735
2023
Q1 		$113K Buy
8,570
+6,595
+334% +$105K 0.01% 673
2022
Q4 		$29.6K Sell
1,975
-120
-6% -$1.1K ﹤0.01% 723
2022
Q3 		$25K Buy
+2,095
New +$28.3K 0.01% 637
2019
Q1 		– Sell
-3,150
Closed -$72K – 721
2018
Q4 		$72K Sell
3,150
-370
-11% -$10.4K 0.01% 569
2018
Q3 		$113K Buy
+3,520
New +$106K 0.02% 586
2016
Q4 		– Sell
-1,593
Closed -$58K – 687
2016
Q3 		$58K Buy
+1,593
New +$45.7K 0.04% 331

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bayesian Capital Management's RIGL Position: Q2 2024 in Review

Bayesian Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 3,048 shares — an estimated $45.1K sold.

Bayesian Capital Management first reported a position in RIGL in Q3 2016 and held it in 10 quarters. The position peaked at $113K in Q1 2023. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Bayesian Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 3,048 Rigel Pharmaceuticals shares in Q2 2024, an estimated $45.1K.
  • Bayesian Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 10 quarters.
  • Bayesian Capital Management's Rigel Pharmaceuticals position peaked at $113K in Q1 2023.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.